Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
9
ACXP Quote, Financials, Valuation and Earnings
Last price:
$3.45
Seasonality move
:
-17.78%
Day range:
$3.17 - $3.50
52-week range:
$3.17 - $25.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.47x
Volume:
43.3K
Avg. volume:
65.1K
1-year change:
-77.37%
Market cap:
$5.4M
Revenue:
--
EPS (TTM):
-$6.49
Analysts' Opinion
-
Consensus RatingAcurx Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $61.70, Acurx Pharmaceuticals, Inc. has an estimated upside of 1672.99% from its current price of $3.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $3.48.
Fair Value
-
According to the consensus of 1 analyst, Acurx Pharmaceuticals, Inc. has 1672.99% upside to fair value with a price target of $61.70 per share.
ACXP vs. S&P 500
-
Over the past 5 trading days, Acurx Pharmaceuticals, Inc. has underperformed the S&P 500 by -7.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Acurx Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Acurx Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Acurx Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Acurx Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Acurx Pharmaceuticals, Inc. reported earnings per share of -$1.23.
Enterprise value:
-553.9K
EV / Invested capital:
-0.15x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-170.39%
Net Income Margin (TTM):
--
Return On Equity:
-358.38%
Return On Invested Capital:
-358.38%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$12.7M | -$16.4M | -$9.2M | -$2.8M | -$2M | |
| EBITDA | -$12.7M | -$16.4M | -$9.2M | -$2.8M | -$2M | |
| Diluted EPS | -$1.05 | -$1.10 | -$6.49 | -$0.17 | -$1.23 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $15M | $10.9M | $7.2M | $6M | $6.1M | |
| Total Assets | $15M | $10.9M | $7.2M | $6M | $6.1M | |
| Current Liabilities | $712.4K | $1.2M | $3.2M | $3.3M | $2.5M | |
| Total Liabilities | $712.4K | $1.2M | $3.2M | $3.3M | $2.5M | |
| Total Equity | $14.3M | $9.8M | $3.9M | $2.7M | $3.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.1M | -$12.3M | -$7.9M | -$2.2M | -$1.9M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $3.5M | $11M | $8M | $1.6M | $1.7M | |
| Free Cash Flow | -$7.1M | -$12.3M | -$7.9M | -$2.2M | -$1.9M | |
ACXP
Sector
Market Cap
$5.4M
$28.4M
Price % of 52-Week High
13.92%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-121.21%
-1.32%
1-Year Price Total Return
-77.37%
-22.19%
Beta (5-Year)
--
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.66
200-day SMA
Sell
Level
$7.15
Bollinger Bands (100)
Sell
Level
3.81 - 6.87
Chaikin Money Flow
Buy
Level
17.1M
20-day SMA
Sell
Level
$4.25
Relative Strength Index (RSI14)
Sell
Level
35.61
ADX Line
Sell
Level
21.04
Williams %R
Buy
Level
-82.1427
50-day SMA
Sell
Level
$5.20
MACD (12, 26)
Sell
Level
-0.53
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
43.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-33.737)
Sell
CA Score
(Annual)
Level (-11.6578)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (18.5691)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, ACXP has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACXP average analyst price target in the past 3 months is $61.70.
-
Where Will Acurx Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Acurx Pharmaceuticals, Inc. share price will rise to $61.70 per share over the next 12 months.
-
What Do Analysts Say About Acurx Pharmaceuticals, Inc.?
Analysts are divided on their view about Acurx Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Acurx Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Acurx Pharmaceuticals, Inc.'s Price Target?
The price target for Acurx Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $61.70 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACXP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Acurx Pharmaceuticals, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ACXP?
You can purchase shares of Acurx Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Acurx Pharmaceuticals, Inc. shares.
-
What Is The Acurx Pharmaceuticals, Inc. Share Price Today?
Acurx Pharmaceuticals, Inc. was last trading at $3.45 per share. This represents the most recent stock quote for Acurx Pharmaceuticals, Inc.. Yesterday, Acurx Pharmaceuticals, Inc. closed at $3.48 per share.
-
How To Buy Acurx Pharmaceuticals, Inc. Stock Online?
In order to purchase Acurx Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ACXP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ACXP
Sector
P/E ratio
--
23.66x
PEG ratio
0.00x
-0.01x
P/B ratio
1.47x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
ACXP
Sector
Revenue growth
--
4.85%
Earnings growth
-610.96%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$1.49
-$0.20
Profitability
ACXP
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-358.38%
-30.98%
Return on assets
-170.39%
-27.62%
Return on equity
-358.38%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
11
Balance Sheet
ACXP
Sector
Total cash
$5.9M
$27.2M
Short term investments
--
$25.7M
Total assets
$3.9M
$79.9M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
